Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orvepitant for EGFR inhibitor-induced intense pruritus
2013-002763-25Phase 2Terminated
- Sponsor
- NeRRe Therapeutics
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of orvepitant in pruritus (3 arms), sponsored by NeRRe Therapeutics. Primary endpoint: Change from baseline in average pruritus intensity at Week 4. Started Aug 2013; status: terminated.
02
Drugs
orvepitant
03
Conditions
pruritus
Beyond the preview
Go deeper on 2013-002763-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002763-25.